medigraphic.com
ISSN 1405-1710 (Print)

2000, Number 2

<< Back Next >>

Rev Cent Dermatol Pascua 2000; 9 (2)

Differential diagnosis of reactions adverse medicinal

Alonzo L, López CLD

Language: Spanish
References: 32
Page: 120-125
PDF size: 46.11 Kb.


ABSTRACT

Drugs can induce adverse reactions at normal dosis and skin eruptions are often cutaneous manifestations of drug-induced reactions. Secondary reactions can be immunological and no immunological, and can coexists with adverse drug interactions. Diagnostic must be clinical, and we can help us with laboratory, in vivo and in vitro, exclusion-induction test and histopathology, they can suggests which drug reaction can be implicated.


REFERENCES

  1. . Malet A, Casajuna I, Huguet J. Estudios inmunológicos in vitro en las toxicodermias. Piel 1992; 7: 36-38.

  2. Arenas. Dermatología, atlas, diagnóstico y tratamiento. Mc Graw-Hill-Interamericana 2ª ed. 1996: 49-53.

  3. Carapeto F. Estrategia para el diagnóstico de las toxicodermias. Piel 1997;12:443-46.

  4. Puig L. Interacciones medicamentosas en dermatología. Piel 1994; 9: 468-76.

  5. Assier H, Bastuji-Garin S, Revuz J et al. Erythema multiforme with mucous membrane involvement and Stevens-Johnson Syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995; 131: 539-543.

  6. Neil H. Diagnóstico de reacciones cutáneas adversas a fármacos. Arch Dermatol 1992; 1(2): 72-76.

  7. Hensin Tsao, Allen R. Cómo descartar una erupción de causa medicamentosa. Review of Dermatology 1996; 3: 3-6.

  8. Allen P, Kaplan MD. Drug –induced skin disease. J Allergy Clin Immunol 1984; 74: 573-79.

  9. Lowitt M, Eisenberg M, Sina B et al. Cutaneous eruptions from suramin, a clinical and histopatologic study of 60 patients. Arch Dermatol 1995; 131: 1147-1153.

  10. Gruppo Italiano Studi Epidemiologici in Dermatologia. Cutaneous reactions to alimentary tract medications: results of a seven-year surveillance program and review of the literature. Dermatology 1996; 193: 11-16.

  11. Hunziker T, Kunzi UP, Braunschweig S et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52(4): 388-393.

  12. Minguez Ma, Zapatero L, Caloto M et al. A study of allergy to penicillin antibiotics in 1995 in the child allergy department of the Gregoriuo Maranon University hospital. Allergol Immunopatol 1998; 26(2): 43-6.

  13. Schopf E. Skin reactions to co-trimoxasole. Infection 1987; 15: S254-8.

  14. Hoigne R, Breymann C, Kunzi UP et al. Parenteral iron therapy: problems and possible solutions. Scheiz Med Wochenschr 1998; 128(14): 528-35.

  15. Whetsel TR, Bell DM. Rash in patients receiving ticlopidine after intracoronary stent placement. Pharmacotherapy 1999; 19(2): 228-31.

  16. Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998; 39(7): S3-7.

  17. Gomez MM, Fernández MC, Domínguez LA et al. Fixed exanthema due to paracetamol. J Investig Allergol Clin Immunol 1996; 6(2): 131-2.

  18. Dascalu DI, Kletter Y, Baratz M et al. Langerhan’s cell distribution in drug eruption. Acta Derm Venereol 1992; 72: 175-177.

  19. Gruppo Italiano Studi Epidemiologici in dermatologia. Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italiano Studi Epidemiologici in Dermatologia. Dermatology 1993; 186(3): 164-9.

  20. Cork. Drug induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol 1997; 136: 645-6.

  21. Bonnetblanc JM. Cutaneous reactions to gold salts. Presse Med 1996; 25(32): 1555-8.

  22. Wach MD. Severe erythema anulare centrifugum-like psoriatic drug eruption induced by terbinafine. Arch Dermatol 1995; 131: 960-1.

  23. Condon CA, Downs AMR, Archer CB. Terbinafine induced acute generalized exanthematous pustulosis. Br J Dermatol 1995; 131: 960-1.

  24. Aquilina C, Viraben R, Roueire A. Acute generalizaed exanthematous pustulosis: a cutaneous adverse effect due to prophylactic antiviral therapy with protease inhibitor. Arch Int Med 1998; 158(19): 2160-1.

  25. Ogoshi M, Yamada Y, Tani M. Acute generalized exanthematic pustulosis induced by cefaclor and acetazolamide. Dermatology 1992; 184(2): 142-4.

  26. Roujeau JC, Bioulac-Sage P, Bourseau C et al. Acute generalizaed exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 1991; 127: 1333-38 .

  27. Freedberg I, Eisen A, Wolff K et al. Fitzpatrick’s. Dermatology in general medicine. Mc Graw-Hill 1999. 5ª ed. 1633-1642.

  28. Halevy S, Grunwald MH, Sandbank M, Buimovice B et al. Macrophage migration inhibitor factor (MIF) in drug eruption. Arch Dermatol 1990; 126: 48-51.

  29. Sánchez RL. Patrones histopatológicos de las reacciones por fármacos. Piel 1993; 8: 38-43.

  30. Hertl M, Bohlen H, Jugert F et al. Predominance of epidermal CD8+ limphocytes in bullous cutaneous reactions caused by b- lactam antibiotics. J Invest Dermatol 1993;101:794-799.

  31. Harman. Severe bullous drug reactions treated with cyclophosphamide. Br J Dermatol 1998; 139: 1111-1137.

  32. Andersen WK, Feingold DS. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 1995; 131: 468-473.




2020     |     www.medigraphic.com